Free tool
FAERS Monitor: Angeliq
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021355 or its brand name (Angeliq, Drospirenone, Estradiol). Reports on generic versions are filed under their own applications.
Reports
540
Serious
312
58% of reports
Hospitalization
102
Death reported
11
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- headache31
- vaginal haemorrhage30
- hot flush26
- fatigue25
- drug ineffective24
- nausea24
- dizziness23
- metrorrhagia23
- alopecia22
- anxiety22
- malaise22
- abdominal pain21
- off label use21
- pain20
- pain in extremity17
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 2 |
| 2006 | 8 |
| 2007 | 7 |
| 2008 | 89 |
| 2009 | 54 |
| 2010 | 16 |
| 2011 | 47 |
| 2012 | 12 |
| 2013 | 29 |
| 2014 | 30 |
| 2015 | 11 |
| 2016 | 19 |
| 2017 | 17 |
| 2018 | 21 |
| 2019 | 21 |
| 2020 | 29 |
| 2021 | 16 |
| 2022 | 17 |
| 2023 | 15 |
| 2024 | 16 |
| 2025 | 60 |
| 2026 | 4 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,619 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| metrorrhagiaSignal | 23 | 52.6 | 35.3 | 1,113 |
| vaginal haemorrhageSignal | 30 | 26.9 | 19.0 | 725 |
| hot flushSignal | 26 | 13.4 | 9.2 | 288 |
| alopeciaSignal | 22 | 4.4 | 2.9 | 54 |
| abdominal painSignal | 21 | 3.5 | 2.3 | 36 |
| anxietySignal | 22 | 3.0 | 2.0 | 28 |
| pain in extremitySignal | 17 | 2.2 | 1.4 | 11 |
| malaise | 22 | 2.0 | 1.3 | 10 |
| headache | 31 | 1.9 | 1.4 | 13 |
| dizziness | 23 | 1.8 | 1.2 | 8 |
| pain | 20 | 1.3 | 0.8 | 1 |
| fatigue | 25 | 1.3 | 0.9 | 1 |
| nausea | 24 | 1.2 | 0.8 | 1 |
| off label use | 21 | 0.9 | 0.6 | 0 |
| drug ineffective | 24 | 0.7 | 0.5 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.